GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » BioCorRx Inc (OTCPK:BICX) » Definitions » Cash Conversion Cycle

BioCorRx (BioCorRx) Cash Conversion Cycle : -17,036.04 (As of Dec. 2023)


View and export this data going back to 2009. Start your Free Trial

What is BioCorRx Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

BioCorRx's Days Sales Outstanding for the three months ended in Dec. 2023 was 31.22.
BioCorRx's Days Inventory for the three months ended in Dec. 2023 was 0.
BioCorRx's Days Payable for the three months ended in Dec. 2023 was 17067.26.
Therefore, BioCorRx's Cash Conversion Cycle (CCC) for the three months ended in Dec. 2023 was -17,036.04.


BioCorRx Cash Conversion Cycle Historical Data

The historical data trend for BioCorRx's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioCorRx Cash Conversion Cycle Chart

BioCorRx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3,068.62 -3,590.00 -89,961.09 -46,080.12 -22,667.71

BioCorRx Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -16,571.71 -23,916.62 -18,383.77 -52,879.38 -17,036.04

Competitive Comparison of BioCorRx's Cash Conversion Cycle

For the Medical Care Facilities subindustry, BioCorRx's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioCorRx's Cash Conversion Cycle Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, BioCorRx's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where BioCorRx's Cash Conversion Cycle falls into.



BioCorRx Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

BioCorRx's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=73.82+0-22741.53
=-22,667.71

BioCorRx's Cash Conversion Cycle for the quarter that ended in Dec. 2023 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=31.22+0-17067.26
=-17,036.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioCorRx  (OTCPK:BICX) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


BioCorRx Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of BioCorRx's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


BioCorRx (BioCorRx) Business Description

Traded in Other Exchanges
N/A
Address
2390 East Orangewood Avenue, Suite 500, Anaheim, CA, USA, 92806
BioCorRx Inc through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders. The BioCorRx Recovery Program is a non-addictive, medication-assisted treatment program for substance abuse that includes peer recovery support. The UnCraveRx Weight Loss Management Program is a medically assisted weight management program that is combined with a virtual platform application.
Executives
Louis C. Lucido director 2390 EAST ORANGEWOOD AVENUE, SUITE 500, ANAHEIM CA 92806
Joseph J Galligan director, 10 percent owner 333 SOUTH GRAND AVENUE, 18TH FLOOR, LOS ANGELES CA 90071
Harsha Murthy director 5209 38TH STREET,NW, WASHINGTON DC 20015
Luisa Ingargiola director 4826 BLUE JAY CIRCLE, PALM HARBOR FL 34683
Thomas Patrick Welch officer: Vice President of Operations 10453 SARAH ST., TOLUCA LAKE CA 91602
Kent Emry director, officer: Chief Executive Officer 2390 EAST ORANGEWOOD AVENUE, SUITE 500, ANAHEIM CA 92806
Brady James Granier director 13024 DELANO STREET, VALLEY GLEN CA 91401
Lourdes Felix director, officer: Chief Financial Officer 15 CALLE VERANO, RANCHO SANTA MARGARITA CA 92688
Jorge Jr Andrade director, officer: Chief Executive Officer PO BOX 5366, SANTA ANA CA 92704
Muller Neil Terrence Mr director, officer: President 13231 SANDHURST PLACE, SANTA ANA CA 92705